Biocon raises Rs 4,500 crore through QIP of equity shares
By Ankur Chandra | Published at: Jun 20, 2025 11:14 AM IST
Bengaluru, June 20: Biocon Limited (NSE: BIOCON) has announced the successful conclusion of its Qualified Institutions Placement (QIP), which involved the allotment of 13.64 crore equity shares.
The placement was executed at an issue price of ₹330 per share, resulting in the company raising a total of ₹4,500 crore. This strategic fundraising initiative is set to significantly strengthen Biocon’s equity capital base, positioning the biopharmaceutical firm for future growth and expansion.
QIP Allotment Summary
The allotment was approved by Biocon’s Fund Raising Committee in a late-night meeting on June 19, 2025. The allotment is in full compliance with Chapter VI of SEBI (ICDR) Regulations, 2018 and Sections 42, 23(1)(b), and 62(1)(c) of the Companies Act, 2013. The allotment follows prior disclosures made in accordance with SEBI LODR Regulation 30 and the SEBI circular dated September 9, 2015.
Share Capital Before And After Allotment
| Particulars | Pre-Allotment | Post-Allotment |
|---|---|---|
| Paid-Up Share Capital (₹) | 600.30 crore | 668.48 crore |
| No. of Equity Shares (FV ₹5 each) | 120.06 crore shares | 133.70 crore shares |
Allotment Structure
| Detail | Description |
|---|---|
| Type of Securities | Equity Shares |
| Mode of Issuance | Qualified Institutions Placement |
| No. of Shares Allotted | 13,63,63,635 |
| Face Value per Share | ₹5 |
| Issue Price per Share | ₹330 (including ₹325 premium) |
| Total Fund Raised | ₹4,500 crore |
| Date of Board Approval (QIP) | April 23, 2025 |
| Date of Allotment | June 19, 2025 |
| Time of Meeting | 11:45 PM to 11:55 PM |
| ISIN | INE376G01013 |
Top Investors In The QIP
Several institutional investors secured significant allocations. As per the annexure included in the disclosure:
- ICICI Prudential (Value Discovery, P.H.D, Equity Savings, Multicap) jointly received 15.39% of the issue.
- SBI Mutual Fund schemes, including Contra Fund, Midcap Fund, and others, were allotted 15.39%.
- HDFC Life Insurance took 7.78% of the issue.
- Aditya Birla Sun Life schemes collectively received 7.22%.
- Nippon Life India MF schemes also secured 7.22%.
- Mirae Asset MF received 7.22% across its funds.
- Franklin Templeton MF schemes were allotted 6.67% in total.
Management Statement
Siddharth Mittal, Managing Director & CEO, signed off the communication, reaffirming Biocon’s adherence to governance and investor transparency standards.
Share Price Effect
The shares of Biocon closed 1.93%, or ₹6.60 higher, at ₹348.60 on June 19th. The shares made an intraday high of ₹350.95 and a low of ₹343.00. It remains to be seen how the shares perform throughout the trading session on June 20.
About Biocon
Biocon Limited is a publicly listed biopharmaceutical company headquartered in Bengaluru, India. It focuses on biosimilars, generics, and novel biologics and operates globally across the US, Europe, and emerging markets. The company’s equity shares are listed on both NSE and BSE under the symbol ‘BIOCON’.
REF: https://nsearchives.nseindia.com/corporate/Bioconlimited_20062025000424_Intimationofallotment.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
